51 results about "Therapy efficacy" patented technology

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

The present invention provides improved and / or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and / or anti-PD-L1 antibody and / or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

The lyophilized formulations comprise steepstercetin, including hydroxyurea methyl acyl fulvene and pharmaceutically acceptable salts thereof, in combination with a cyclodextrin. These formulations are designed to enhance the solubility, stability and therapeutic efficacy of steep steep cephalosporin, which has been illustrated due to its potent anti-cancer properties. Methods for producing these lyophilized formulations are provided, including a lyophilization process.

This invention belongs to the field of tumor detection and relates to a dynamic evaluation method for the efficacy of Bragg therapy driven by multi-cycle, multimodal peripheral blood data. The method includes the following steps: acquiring peripheral blood multimodal data from patients participating in Bragg therapy, and dividing the peripheral blood multimodal data into a training dataset and a validation dataset; constructing a Bragg therapy efficacy evaluation model using the training dataset, and validating the Bragg therapy efficacy evaluation model using the validation dataset; receiving peripheral blood multimodal data from patients participating in Bragg therapy, and calculating the evaluation results using the Bragg therapy efficacy evaluation model. This invention, by combining long short-term memory networks and graph neural networks, can effectively track the temporal changes of immune cell characteristics, thereby providing a more accurate basis for developing personalized treatment plans for Bragg therapy patients, improving treatment outcomes and survival rates.

tFUS delivery and tracking systems and methods assess target location accuracy and therapy efficacy by measuring the specific and predicted downstream effects in individualistic responses to tFUS waveforms. The downstream effects include physiological, stress, mood, movement, attention measurements, subjective reports, task-based performance, etc. The measurements are performed before, during, and between tFUS sessions intermixed with optional control periods or sessions. In an embodiment, when a target brain region does not offer any immediate readouts but is surrounded by regions that may, these latter regions can be used instead for triangulation or waveform optimization. Individual and group tracking methods help identify useful measurement modalities and the expected direction and magnitude of change in response to therapy. A method that enables individualized functional targeting in a non-clinical setting by optimizing cost and complexity is described.

Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and / or for assessing a biological effect, such as therapeutic efficacy and / or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

Methods for treating non-small cell lung cancer (NSCLC) include the administration of a combination of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed. The methods are based on tumor mutational burden (TMB) assessment, with specific treatment regimens tailored to the mutational profile of the tumor. When a low tumor mutational burden is detected in a tumor sample, the combination therapy of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed is administered, offering enhanced therapeutic efficacy.

A composition contains (i) rapamycin and / or a rapalog and (ii) a radiolabeled gastrin analogue. The composition can be used for the treatment and / or diagnosis of CCKB receptor positive cancer or tumors and leads to superior tumor uptake of radiolabeled gastrin analogue, resulting in improved delivery and therapeutic efficacy while cytotoxic side-effects are prevented and / or reduced.

A system and method for distinguishing non-failing from failing cardiac fibroblasts (CFs) using advanced imaging techniques and machine learning (ML). The method involves staining CFs with fluorescent dyes to highlight key cellular components, such as nuclei and actin fibers. Images are analyzed to extract morphological features, which are then processed and normalized. A supervised ML system, trained on labeled CF data, classifies CFs based on phenotypic differences. The system enables accurate diagnosis of heart failure (HF), facilitates screening for therapeutic efficacy, and identifies antifibrotic agents by evaluating changes in CF phenotypes pre- and post-treatment.

Provided herein are biomarkers useful for identifying patients suitable for therapy comprising immune checkpoint inhibitors, and methods of using these biomarkers. In particular, the present disclosure provides techniques for treating and predicting cancer in a patient using biomarker expression levels in a biological sample obtained from the patient, as well as techniques for determining the likelihood that a patient will respond to therapy comprising an immune checkpoint inhibitor.

The present invention pertains to methods for survival prognosis, stratification, and assessment of disease progression or regression in Glioblastoma multiforme (GBM) patients. These methods are based on the detection and analysis of signature patterns of six specific metabolites in emotional tears samples. Additionally, the invention encompasses a preparation technique for emotional tears samples prior to liquid chromatography-mass spectrometry (LC-MS) analysis. This approach enables more accurate and reliable evaluation of GBM patient status and treatment efficacy through the examination of emotional tears metabolite profiles.

1. Name of the product in this design: Interactive graphical user interface for an oxygen chamber therapy effect evaluation system for electronic devices. 2. Intended use of this design: for use in an electronic device. 3. The key design feature of this product is its graphical user interface. 4. The image or photograph that best illustrates the design's key features: the front view. 5. Other orthographic views and perspective views are omitted. 6. Purpose of the graphical user interface: To display the main workflow and content of the hyperbaric oxygen therapy department. 7. Description of the changing states of the graphical user interface: The main view is the login interface; Figure 1 shows the interactive interface displayed after entering the correct username and password in the main view and clicking the "Login to System" button; Figure 2 shows the interactive interface displayed after clicking "Admission Treatment Management" in Figure 1; Figure 3 shows the interactive interface displayed after clicking "First Chamber" in Figure 2; Figure 4 shows the interactive interface displayed after clicking "Treatment Records" in Figure 3.

DEPCT64 This invention relates to 4 / 91IBV (Infectious Bronchitis Virus) which is coded for... Heterologous S (spike) protein or fragments thereof; furthermore, this invention also... This is related to the components that elicit an immune response, which include the aforementioned 4 / 91IBV. Process the code for heterologous S (spike) protein or fragments thereof. This invention also relates to a method for immunizing targets, which includes: Providing the target with an element that induces an immune response to this invention. Furthermore, this invention relates to methods for treating or preventing clinical symptoms caused by IBV. The necessary objectives involve a method of providing the target with the required quantity. The therapeutic efficacy of the immune response-inducing components according to this invention. -----------------------------------------------------------

The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

A method for treating brain injury in a subject comprises administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant. The protein variant is delivered systemically and can reduce tissue damage after ischemic brain tissue reperfusion. The methods specifically involve the use of G415R mutants of PKM2 protein variants. The treatment is suitable for brain injury caused by hemorrhagic stroke and ischemic stroke. The PKM2 protein variants are ideally administered intravenously within one hour of reperfusion to maximize their therapeutic efficacy.

Described are methods for enhancing cancer immune surveillance and the efficacy of the treatment of melanoma or non-melanoma cancers such as pancreatic or colorectal cancers, particularly by controlling cancer cell-surface PD-L1 / L2 and the E3 ligase ITCH. Also described are methods of inhibiting an adaptive immune resistance response to anti-immune checkpoint protein therapy in a subject. As described herein, the efficacy of MAPK inhibitor therapy is increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1 / L2. As further demonstrated herein, the efficacy of anti-PD-1 / L1 therapy is also increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1 / L2.

Disclosed herein are methods and systems for detecting microorganisms in a sample and the use of such methods for selecting and monitoring therapies. The specificity of an indicator bacteriophage, such as a Staphylococcus specific bacteriophage, allows the detection of a particular microorganism, such as Staphylococcus, and the indicator signal can be amplified to optimize assay sensitivity.

Disclosed are methods for determining the pharmacodynamic activity of one or more compounds by measurement of focal accumulation of CIP2A. Further disclosed are methods of determining the effectiveness of a treatment with one or more compounds b measurement of focal accumulation of CIP2A. Compounds of the invention may be Polθ kinase inhibitors or PARP inhibitors.

The invention provides methods for cancer diagnosis, for predicting recurrence and minimal residual disease, and for informing therapeutic choice / predicting therapeutic efficacy. The invention comprises extracting cfDNA from a bodily fluid sample and performing size selection to extract cfDNA from the sample. The size selection step may be performed any number of times as is suitable to obtain a desired yield.

This invention relates to an instrument for treating neurological or psychiatric disorders using i-wave periodicity-dependent four-pulse theta burst stimulation (iQPS). The system includes a transcranial magnetic stimulation (TMS) stimulator configured to deliver test pulses to a target motor cortex region and therapeutic theta bursts to a treatment region, wherein the pulse frequency is customized according to the patient's individual i-wave periodicity. An electromyography (EMG) device records motor evoked potentials (MEPs) from the target muscles and analyzes the intervals between MEPs to determine the i-wave periodicity. Personalized stimulation enhances cortical plasticity by synchronizing stimulation with the brain's intrinsic neural timing. This invention is applicable to neurological and psychiatric conditions including depression, schizophrenia, stroke recovery, and neuropathic pain. Advantages include improved therapeutic efficacy, reduced patient response variability, and a non-invasive adaptive therapy model aligned with the patient's unique neurophysiological characteristics, thus providing a precise and scalable approach to brain stimulation.

The present specification discloses modified anti-PD-Ll antibodies that eliminate Fc- associated effector functions and enhance clearance while maintaining therapeutic efficacy on neurodegenerative disease alterations. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-Ll antibodies, and methods of making such modified anti-PD-Ll antibodies. In addition, the present specification discloses methods of treatment and uses employing administration regimens of the disclosed anti-PD-Ll antibodies that ensure that the antibodies are only present for a specific period of time and then are sufficiently cleared from the body to ensure maintenance of therapeutic efficacy.

The invention features the use of coelenterazine or similar analogs as a real-time reporter for systemic administration of ROS or RNS levels in the animal cell and organ environment. This real-time measurement can then be used to assess the severity of free radical dependent disease states, such as neurodegenerative disease, ischemia-reperfusion injury after organ transplantation, acute radiation syndrome injury, and the like. Methods may include real-time measurement of therapeutic efficacy of PrC-210 as a radical scavenger capable of eliminating oxygen and nitrogen radicals.

Disclosed herein are UNC13A oligonucleotides having one or more spacer regions or having no spacer regions. In various embodiments, UNC13A oligonucleotides with spacer regions can reduce misspliced UNC13A transcripts and increase full-length UNC13A transcripts, resulting in therapeutic efficacy on nervous system diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

A cyclocurcumin-based composition comprising: cyclocurcumin in an amount of 25 to 40% by weight of the total composition; one or more residual curcuminoids, including curcumin and demethoxycurcumin, in a total amount of 8 to 18% by weight; an antioxidant stabilizer selected from ascorbic acid, tocopherol, or a combination thereof in an amount of 3 to 8% by weight; a bioavailability enhancer containing piperine in an amount of 1 to 3% by weight; and a pharmaceutically acceptable excipient in an amount of 40 to 60% by weight.

The present disclosure relates to determining an efficacy of a therapeutic agent. A method for determining an efficacy of a therapeutic agent for a target disease can include measuring a molecular structure of a biological tissue of an animal at a first time and at a second time using a non-invasive biological tissue characterization technique. The method can further include observing a change of the molecular structure of the biological tissue between the first time and the second time, and determining the efficacy of the therapeutic agent based on the observed change in the molecular structure of the biological tissue. Before the first time, or between the first time and the second time, the animal received the therapeutic agent.

Method and compositions for treating glioblastoma (GBM) and other cancers is disclosed, involving the combination of radiation therapy (RT), fatty acid synthase (FASN) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors or programmed death ligand 1 (PD-L1) inhibitors. The disclosed approach addresses the technical problem of RT-induced immunosuppression and resistance in cancers by targeting RT-induced lipid metabolism, which promotes immune escape. FASN inhibitors block fatty acid synthesis, enhancing immune cell infiltration and restoring anti-tumor immunity. PD-1 / PD-L1 inhibitors further counteract immunosuppressive pathways to improve therapeutic efficacy. This combination therapy prolongs survival, induces immune memory, and is applicable to other cancers, including those exhibiting increased lipid content post-RT or chemotherapy, including melanoma, breast cancer, and lung cancer.

The present disclosure provides a cytokine-based bioactivatable drug construct (“VitoKine”) platform that aims to reduce systemic mechanism-based toxicities and lead to broader therapeutic utility for proteins and cytokines such as IL-15 and IL-2 for the treatment of cancer, autoimmune diseases, inflammatory diseases, viral infection, transplantation and various other disorders. The novel VitoKine constructs of the present invention comprise: 1) a tissue or disease site targeting moiety D1 domain (“D1”), 2) a bioactivatable moiety D2 domain (“D2”), and a concealing moiety D3 domain (“D3”). Importantly, because the “active moiety” of the VitoKine construct will remain inert until activated locally by proteases that are upregulated in diseased tissues, this will limit binding of the active moiety to the receptors or to the targets in the peripheral or on the cell-surface of non-diseased cells and tissue to prevent over-activation of the pathway and reduce undesirable “on-target”“off tissue” toxicities. Additionally, the inertness of the VitoKine active moiety prior to protease activation will significantly decrease the potential antigen or target sink, and thus, prolong the in vivo half-life and result in improved biodistribution, bioavailability and therapeutic efficacy.

Methods and systems for treating sleep disordered breathing and assessing and improving efficacy of treatment of sleep disordered breathing re disclosed herein. According to some embodiments, the present technology includes a method of treating sleep disordered breathing with a neuromodulation system at least partially implanted in a patient having an airway compromised by an obstruction. The method includes delivering stimulation energy to a target nerve in the patient using an electrode of the neuromodulation system, wherein the target nerve is associated with patency of the airway, receiving sensor data from a sensor arrangement of the neuromodulation system, wherein the sensor data is indicative of airflow in the airway proximal to the obstruction, and assessing efficacy of the stimulation energy based at least in part on the received sensor data.

The invention provides methods for cancer diagnosis, for predicting recurrence and minimal residual disease, and for informing therapeutic choice / predicting therapeutic efficacy. The invention comprises extracting cfDNA from a bodily fluid sample and performing size selection to extract cfDNA from the sample. The size selection step may be performed any number of times as is suitable to obtain a desired yield.